
Tasca Begins Phase 1/2 Trial of CP-383 in Advanced Solid Tumors
Tasca Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of CP-383 for Advanced Solid Tumors Tasca Therapeutics, a clinical-stage biotechnology company dedicated to developing targeted therapies for genetically defined cancers, announced today that the first patient has been dosed…












